Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polyrizon Ltd. ( (PLRZ) ) has issued an announcement.
On February 26, 2026, Polyrizon Ltd. reported results from a comparative study of its naloxone nasal formulation conducted at the University of Parma’s Biopharmanet-TEC center. Using a validated silicone nasal cast model, the company showed its formulation achieved higher deposition in the highly vascularized nasal vestibule and upper turbinate region than a commercial reference product.
The study found Polyrizon’s formulation delivered 94.6% of the dose to the upper/anterior nasal region versus 79.6% for the reference product, while reducing lower turbinate deposition and potential posterior runoff. The data support the differentiation of Polyrizon’s Trap & Target intranasal platform and could enhance the competitiveness of its naloxone program by suggesting improved systemic absorption and more consistent dosing compared with existing commercial options.
More about Polyrizon Ltd.
Polyrizon Ltd. is a pre-clinical-stage biotechnology company focused on intranasal drug delivery solutions and medical device hydrogels. Its core Capture and Contain hydrogel nasal sprays aim to create a “biological mask” barrier against viruses and allergens, while its Trap & Target platform is being developed for targeted intranasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 3,269,506
Technical Sentiment Signal: Sell
Current Market Cap: $22.32M
Learn more about PLRZ stock on TipRanks’ Stock Analysis page.